Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study

NCT07450027 is registered in ClinicalTrials.gov with Elazığ Mental Health and Diseases Hospital as lead sponsor.

NCT NCT07450027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07450027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study
Lead sponsor
Elazığ Mental Health and Diseases Hospital
Phase
Observational
Overall status
Completed
Start date
September 1, 2025
Completion date
April 1, 2026
Enrollment
111 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine use disorder, methamphetamine-induced psychosis